Short Interest in Evogene Ltd. (NASDAQ:EVGN) Expands By 154.6%
by Michael Walen · The Markets DailyEvogene Ltd. (NASDAQ:EVGN – Get Free Report) was the recipient of a significant growth in short interest during the month of June. As of June 15th, there was short interest totaling 313,620 shares, a growth of 154.6% from the May 31st total of 123,199 shares. Currently, 3.9% of the company’s stock are sold short. Based on an average daily trading volume, of 2,420,901 shares, the days-to-cover ratio is currently 0.1 days.
Hedge Funds Weigh In On Evogene
A number of institutional investors have recently modified their holdings of EVGN. XTX Topco Ltd acquired a new stake in shares of Evogene in the fourth quarter worth $25,000. Citadel Advisors LLC lifted its position in Evogene by 169.4% during the 3rd quarter. Citadel Advisors LLC now owns 57,575 shares of the biotechnology company’s stock worth $66,000 after acquiring an additional 36,206 shares during the last quarter. Finally, Jane Street Group LLC boosted its holdings in Evogene by 58.0% during the first quarter. Jane Street Group LLC now owns 33,732 shares of the biotechnology company’s stock valued at $42,000 after acquiring an additional 12,387 shares during the period. Institutional investors own 10.40% of the company’s stock.
Evogene Stock Up 0.1%
Shares of NASDAQ:EVGN traded up $0.00 on Tuesday, reaching $0.43. The company had a trading volume of 118,301 shares, compared to its average volume of 789,307. The stock has a market capitalization of $3.77 million, a P/E ratio of -0.31 and a beta of 1.35. The stock has a 50-day moving average price of $0.67 and a 200 day moving average price of $0.85. Evogene has a twelve month low of $0.37 and a twelve month high of $1.50.
Evogene (NASDAQ:EVGN – Get Free Report) last issued its quarterly earnings data on Saturday, May 16th. The biotechnology company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.33). Evogene had a negative net margin of 638.12% and a negative return on equity of 158.82%. The company had revenue of $0.33 million for the quarter, compared to analyst estimates of $0.35 million.
Evogene Company Profile
Evogene Ltd. is a biotechnology company specializing in the use of computational and predictive biology technologies to design and develop novel products for agriculture and human health. Founded in 2002 and headquartered in Rehovot, Israel, the company has built a proprietary computational platform that integrates genomics, machine learning and data analytics to identify gene targets and biological traits. Evogene’s platform serves as the backbone for its research and development efforts, enabling the discovery of enhanced crop traits, microbial solutions and microbiome-based diagnostics and therapeutics.
In the agricultural sector, Evogene applies its platform to improve crop performance across a range of parameters, including yield enhancement, stress tolerance and resistance to pests and pathogens.